Show simple item record

dc.contributor.authorGomez-Peralta, Fernando
dc.contributor.authorAbreu, Cristina
dc.contributor.authorLecube Torelló, Albert
dc.contributor.authorBellido, Diego
dc.contributor.authorSoto, Alfonso
dc.contributor.authorMorales, Cristóbal
dc.contributor.authorBrito-Sanfiel, Miguel
dc.contributor.authorUmpierrez, Guillermo
dc.date.accessioned2017-11-20T11:01:19Z
dc.date.available2017-11-20T11:01:19Z
dc.date.issued2017
dc.identifier.issn1869-6953
dc.identifier.urihttp://hdl.handle.net/10459.1/60512
dc.description.abstractSodium-glucose co-transporter 2 (SGLT2) inhibitors are an attractive novel therapeutic option for the treatment of type 2 diabetes. They block the reabsorption of filtered glucose in kidneys, mainly in proximal renal tubules, resulting in increased urinary glucose excretion and correction of the diabetes-related hyperglycemia. Beyond improving glucose control, SGLT2 inhibitors offer potential benefits by reducing body weight and blood pressure. On the basis of the efficacy demonstrated in clinical trials, SGLT2 inhibitors are recommended as second- or third-line agents for the management of patients with type 2 diabetes. Beneficial effects on kidney disease progression, cardiovascular and all-cause mortality, and hospitalization for heart failure have also been demonstrated with one SGLT2 inhibitor (empagliflozin). Potential adverse events resulting from their mechanism of action or related to concomitant therapies are reviewed. A treatment algorithm for the adjustment of concomitant therapies after initiating SGLT2 inhibitors is also proposed.ca_ES
dc.description.sponsorshipAstra-Zeneca España contributed to support medical writing activities provided by Meysis S.L. No other external funding was received for this manuscript, which was written thanks to the unconditional effort of all authors.ca_ES
dc.language.isoengca_ES
dc.publisherSpringer Verlagca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.1007/s13300-017-0277-0ca_ES
dc.relation.ispartofDiabetes Therapy, 2017, vol. 8, núm. 5, p. 953-962ca_ES
dc.rightscc-by-nc (c) Gomez-Peralta et al., 2017ca_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectConcomitantca_ES
dc.subjectInitiationca_ES
dc.subjectManagementca_ES
dc.subjectSGLT2 inhibitorsca_ES
dc.titlePractical approach to initiating SGLT2 inhibitors in type 2 diabetesca_ES
dc.typearticleca_ES
dc.type.versionpublishedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.identifier.doihttps://doi.org/10.1007/s13300-017-0277-0


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

cc-by-nc (c) Gomez-Peralta et al., 2017
Except where otherwise noted, this item's license is described as cc-by-nc (c) Gomez-Peralta et al., 2017